Exploring the Therapeutic Potential of the Ketogenic Diet on Neurological Disorders: A Comprehensive Review

Sai Krishna Vallamchetla
All India Institute of Medical Sciences, Bhopal, India

ABSTRACT

The ketogenic diet (KD) has emerged as a promising therapeutic strategy for a variety of neurological disorders, including epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and autism spectrum disorder. The potential benefits of the KD are attributed to its capacity to modulate neurotransmission, reduce inflammation, improve mitochondrial function, and enhance synaptic plasticity. Despite the growing body of evidence supporting the KD's therapeutic potential, there remain challenges in its implementation, such as potential side effects, nutrient deficiencies, and the need for careful monitoring by healthcare professionals. Factors affecting the success of the KD include patient adherence, individual metabolic response, and appropriate diet customization. This review summarizes the current evidence supporting the KD's role in the management of neurological disorders, discusses the underlying mechanisms of action, highlights the challenges and considerations associated with its use, and addresses the factors that can influence treatment success. Further research is needed to optimize the KD for different patient populations, elucidate the specific therapeutic mechanisms, and identify potential biomarkers to predict treatment response, ultimately enhancing the quality of life and overall well-being of individuals affected by neurological disorders.

Introduction

The ketogenic diet (KD), a high-fat, low-carbohydrate dietary approach, was originally developed in the 1920s to treat epilepsy. Over the past few decades, this diet has gained considerable attention in the field of neurology for its potential role in managing various neurological disorders beyond epilepsy. The KD is known to induce a state of ketosis, where the body relies on ketone bodies produced from fat metabolism rather than glucose for energy. This shift in energy metabolism has been suggested to exert neuroprotective effects and modulate various cellular processes, which could be beneficial for treating neurological conditions.

Research on the KD has expanded to include its potential application in the management of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and autism spectrum disorder. Studies have indicated improvements in cognitive function, motor symptoms, and overall quality of life in patients following a KD regimen. The mechanisms through which the KD may exert its therapeutic effects in these disorders are not yet fully understood, but they are thought to involve reduced oxidative stress, enhanced mitochondrial function, and modulation of neurotransmitter systems.

Despite the promising findings, implementing the KD as a therapeutic approach for neurological disorders is not without challenges. Adherence to the diet can be difficult for patients, and potential side effects, such as gastrointestinal disturbances and nutrient deficiencies, must be carefully managed. Additionally, more large-scale, well-controlled studies are...
needed to determine the long-term safety and efficacy of the KD in various neurological populations. In this comprehensive review, we summarize the current knowledge on the role of the KD in various neurological disorders, discuss its potential mechanisms of action, and address the challenges faced in implementing the diet as a therapeutic strategy.

**Methodology**

To provide a comprehensive review of the role of the ketogenic diet (KD) in the management of neurological disorders, we conducted a systematic search of the literature using the PubMed and Google Scholar from inception till 2022. The keywords and search terms used in the search strategy included “ketogenic diet,” “epilepsy,” “Alzheimer’s disease,” “Parkinson’s disease,” “multiple sclerosis,” “autism spectrum disorder”.

Inclusion criteria for the studies were as follows: (1) original research articles (randomized controlled trials, cohort studies, case-control studies, and case reports); (2) articles investigating the effects of the KD on patients with neurological disorders; (3) articles evaluating the safety, efficacy, and mechanisms of action of the KD in neurological disorders; and (4) articles discussing challenges and strategies for implementing the KD as a therapeutic intervention. Exclusion criteria included (1) non-original research articles (e.g., reviews, editorials, and commentaries); (2) articles not focused on the KD; (3) articles not related to neurological disorders; and (4) articles with insufficient data or methodology; (5) Animal studies of neurological disorders for which sufficient clinical evidence already exists.

### Ketogenic Diet and Neurological Disorders

#### Ketogenic Diet and Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately 65 million people worldwide (20), with nearly 3 million affected individuals in the United States alone (21). It is characterized by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. About 30% of epilepsy cases are considered drug-resistant, meaning that patients do not achieve seizure control with standard anti-seizure medications (22). The ketogenic diet has been demonstrated as an effective treatment option for drug-resistant epilepsy, particularly in pediatric populations. Its efficacy is supported by numerous studies and long-term outcome data, showing improvements in seizure control for many patients. Some key studies are shown in Table 1.

#### Table 1: Evidence Supporting the Ketogenic Diet in Epilepsy Management

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal et al. (28)</td>
<td>RCT</td>
<td>145 children</td>
<td>38% children in the diet group had greater than 50% seizure reduction compared with four (6%) controls (p=0.0001) after 3 months</td>
</tr>
<tr>
<td>Ye et al. (29)</td>
<td>Meta-analysis</td>
<td>12 studies (270 adults)</td>
<td>Meta-analysis of 12 studies yielded a combined efficacy rate of the KD of 42%, with significant heterogeneity.</td>
</tr>
<tr>
<td>Martin-McGill et al. (30)</td>
<td>Systematic Review</td>
<td>11 studies (712 children and adolescents, 66 adults.)</td>
<td>After three months, reported rates of seizure freedom in a classical 4:1 KD group reached as high as 55%, while reported rates of seizure reduction reached as high as 85%.</td>
</tr>
<tr>
<td>Kossoff et al. (31)</td>
<td>Retrospective study</td>
<td>118 children</td>
<td>At 6 months, 71% children were&gt;50% improved and 43% children were&gt;90% improved.</td>
</tr>
<tr>
<td>Sharma et al. (32)</td>
<td>RCT</td>
<td>102 children</td>
<td>The proportion of children with &gt;90% seizure reduction (30% vs. 7.7%, p = 0.005) and &gt;50% seizure reduction was significantly higher in the diet group (52% vs. 11.5%, p &lt; 0.001) in comparison with controls.</td>
</tr>
<tr>
<td>Henderson et al. (33)</td>
<td>Meta-analysis</td>
<td>19 studies (1084 children)</td>
<td>The pooled odds ratio, using a random effects model, of treatment success (&gt;50% seizure reduction) among patients staying on the diet relative to those discontinuing the diet was 2.25 (95% confidence interval = 1.69-2.98).</td>
</tr>
<tr>
<td>Klein et al. (34)</td>
<td>Prospective open-label pilot study</td>
<td>12 adults</td>
<td>In all adults there was &gt;75% seizure reduction, the full effect occurred during the first month of treatment.</td>
</tr>
<tr>
<td>Cervenka et al. (35)</td>
<td>Prospective study</td>
<td>24 adults</td>
<td>Of the 14 patients who completed KD treatment, 11 experienced resolution of super-refractory status epilepticus.</td>
</tr>
<tr>
<td>Suo et al. (36)</td>
<td>Prospective study</td>
<td>317 children</td>
<td>After 12 months, 24.3% stayed on the KD diet, 18.6% had &gt;50% seizure reduction, and 10.7% were seizure-free.</td>
</tr>
<tr>
<td>Lambrechts et al. (37)</td>
<td>Prospective study</td>
<td>15 adults</td>
<td>5 patients who followed the diet for 1 year showed significant reduction in seizures. Of these 5 patients, 2 had a reduction between 50 and 90%.</td>
</tr>
<tr>
<td>Wirrell et al. (38)</td>
<td>Retrospective study</td>
<td>14 children</td>
<td>In 5 of 12 children (42%), the ketogenic diet succeeded, leading to either medication withdrawal (n=3) or reduction (n=2).</td>
</tr>
<tr>
<td>Carrette et al. (39)</td>
<td>Prospective study</td>
<td>8 adults</td>
<td>A comparison of seizure frequency in three patients who completed the study showed a mean reduction of 42.2% (range: 25-60%) from baseline to the final month (6th).</td>
</tr>
<tr>
<td>Mosek et al. (40)</td>
<td>Prospective study</td>
<td>9 adults</td>
<td>After 12 weeks of follow up, two patients who concluded the study had a more than 50% reduction in the frequency of the seizures.</td>
</tr>
</tbody>
</table>
Mechanisms Underlying the KD’s Effects in Epilepsy:
The ketogenic diet (KD) has been shown to be effective in managing epilepsy, but the exact mechanisms underlying its effects are still not entirely understood. Some proposed mechanisms include:

a) Enhanced energy metabolism: KD leads to a metabolic shift from glucose utilization to ketone bodies (such as β-hydroxybutyrate, acetoacetate, and acetone) as the primary source of energy for the brain. This shift may stabilize neuronal activity and reduce seizure susceptibility.

b) Reduced neuronal excitability: The KD may decrease neuronal excitability by altering neurotransmitter systems, such as increasing the brain's gamma-aminobutyric acid (GABA) levels, an inhibitory neurotransmitter, and reducing the levels of excitatory neurotransmitters like glutamate.

c) Modulation of ion channels: The KD may alter the function of various ion channels, such as ATP-sensitive potassium channels, voltage-gated sodium channels, and voltage-gated calcium channels, which can stabilize neuronal membrane potential and reduce seizure susceptibility.

d) Anti-inflammatory effects: The KD may have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines, which can contribute to seizure susceptibility.

e) Epigenetic modifications: KD may induce changes in gene expression through histone modifications and DNA methylation, which can influence neuronal excitability and seizure susceptibility.

Ketogenic Diet and Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. It is characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein, leading to neuronal loss and cognitive decline. Current treatments for AD primarily focus on symptom management, and there is no cure for the disease. Several clinical studies have investigated the effects of the KD or ketone supplements in patients with AD as shown in Table 2. The evidence suggests that the ketogenic diet may have potential benefits in the management of Alzheimer’s disease by improving cognitive function, memory, and brain energy metabolism.

Mechanisms Underlying the KD’s Effects in Alzheimer’s Disease:
The ketogenic diet (KD) has shown promise in Alzheimer’s disease (AD) management, and several mechanisms have been proposed to explain its potential benefits:

a) Improved brain energy metabolism: KD may help overcome the brain glucose hypometabolism commonly observed in AD by providing ketone bodies as an alternative fuel source, thereby enhancing neuronal function and resilience.

b) Reduction in oxidative stress: KD has been shown to upregulate antioxidant defenses and reduce the production of reactive oxygen species, which can cause oxidative damage to neurons in AD.

c) Modulation of amyloid-beta and tau pathology: Some studies suggest that KD may help reduce the accumulation of Aβ plaques and hyperphosphorylated tau levels, potentially slowing AD progression.

d) Enhancement of mitochondrial function: KD may improve mitochondrial function and biogenesis, which are often impaired in AD.

e) Neuroinflammation reduction: KD can modulate the immune system and reduce neuroinflammation, which is implicated in AD development and progression.

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Participants</th>
<th>Intervention</th>
<th>Duration</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krikorian et al.</td>
<td>RCT</td>
<td>23 older adults with MCI</td>
<td>Low-carbohydrate diet</td>
<td>6 weeks</td>
<td>Improved cognitive performance</td>
</tr>
<tr>
<td>Taylor et al.</td>
<td>Prospective study</td>
<td>15 with mild-to-moderate AD</td>
<td>KD intervention</td>
<td>12 weeks</td>
<td>Significant improvements in memory and cognition</td>
</tr>
<tr>
<td>Ota et al.</td>
<td>Prospective study</td>
<td>20 with mild-to-moderate AD</td>
<td>Medium-chain triglyceride (MCT)-based ketogenic diet</td>
<td>12 weeks</td>
<td>Increased ketone body levels and significant cognitive improvement</td>
</tr>
<tr>
<td>Henderson et al.</td>
<td>RCT</td>
<td>152 with mild-to-moderate AD</td>
<td>Medium-chain triglyceride (MCT)-based ketogenic diet</td>
<td>90 days</td>
<td>Improved cognitive performance</td>
</tr>
<tr>
<td>Fortier et al.</td>
<td>RCT</td>
<td>83 with MCI</td>
<td>Medium-chain triglyceride (MCT)-based ketogenic diet</td>
<td>6 months</td>
<td>Improved cognitive function.</td>
</tr>
<tr>
<td>Newport et al.</td>
<td>Case report</td>
<td>1 with severe AD</td>
<td>Ketone monoester (KME)</td>
<td>20 months</td>
<td>Improved cognitive function.</td>
</tr>
<tr>
<td>Phillips et al.</td>
<td>RCT (cross over trail)</td>
<td>26 with AD</td>
<td>Ketogenic diet</td>
<td>12 weeks</td>
<td>Improved cognitive function, Quality of life</td>
</tr>
</tbody>
</table>
Ketogenic Diet and Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor dysfunction, cognitive decline, and other non-motor symptoms\(^5\). Evidence suggests that ketogenic diet has shown promise in alleviating some symptoms of Parkinson’s disease, such as motor dysfunction and cognitive decline as shown in Table 3.

**Mechanisms Underlying the KD’s Effects in Parkinson’s Disease:**

a) Enhanced mitochondrial function: The KD has been shown to improve mitochondrial function and biogenesis, which is often impaired in PD, leading to energy deficits and increased vulnerability to neurodegeneration\(^4\).

b) Reduction of inflammation: The KD may modulate the immune system and reduce neuroinflammation, which is implicated in PD development and progression\(^5\).

c) Promotion of neurogenesis: The KD may enhance the expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), which can support the growth, survival, and differentiation of neurons and may help alleviate PD symptoms\(^5\).

d) Antioxidant effects: The KD has been shown to upregulate antioxidant defenses and reduce the production of reactive oxygen species, which can contribute to oxidative stress and neurodegeneration in PD\(^4\).

### Table 3: Evidence Supporting the Ketogenic Diet in Parkinson’s Disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Follow-up Period</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanitallie et al.(^5)</td>
<td>Prospective Study</td>
<td>7 patients</td>
<td>28 days</td>
<td>The mean total decrease in Unified Parkinson’s Disease Rating Scale (UPDRS) scores for five participants who completed the study was 43.4% (ranging from 21 to 81).</td>
</tr>
<tr>
<td>Phillips et al.(^54)</td>
<td>Randomized controlled trial</td>
<td>47 patients</td>
<td>8 weeks</td>
<td>Both the ketogenic diet (KD) and low-fat diet groups experienced significant improvements in motor and nonmotor symptoms, with the ketogenic group demonstrating more substantial improvements in nonmotor symptoms.</td>
</tr>
<tr>
<td>Cheng et al.(^46)</td>
<td>Rat Model</td>
<td>NA</td>
<td>NA</td>
<td>The KD exhibited neuroprotective effects against 6-hydroxydopamine (6-OHDA) neurotoxicity, with glutathione playing a crucial role during this period.</td>
</tr>
<tr>
<td>Kashiwaya et al.(^56)</td>
<td>Rat brain mitochondria</td>
<td>NA</td>
<td>NA</td>
<td>Ketone body administration has the potential to offer symptomatic relief and neuroprotection in Parkinson’s disease by circumventing the mitochondrial complex I defect.</td>
</tr>
<tr>
<td>Tieu et al.(^56)</td>
<td>Rat model</td>
<td>NA</td>
<td>NA</td>
<td>Ketone bodies can safeguard against MPTP-induced neurotoxicity, indicating that the ketogenic diet may possess therapeutic potential for Parkinson’s disease.</td>
</tr>
<tr>
<td>Shaafi et al.(^57)</td>
<td>Rat model</td>
<td>NA</td>
<td>4 weeks</td>
<td>In comparison to those on a standard diet, rats with Parkinson’s disease fed a ketogenic diet exhibited significant enhancements in motor function.</td>
</tr>
</tbody>
</table>

Ketogenic Diet and Multiple Sclerosis

Multiple sclerosis is an autoimmune disorder characterized by the demyelination of neurons in the central nervous system\(^5\). While the KD has not been studied as extensively in multiple sclerosis as in other neurological disorders, Evidence suggests potential benefits as shown in Table 4.

**Mechanisms Underlying the KD’s Effects in Multiple Sclerosis:**

a) Reduction of inflammation: The KD has been shown to modulate the immune system and reduce pro-inflammatory cytokines, which may help alleviate inflammation-mediated damage in MS\(^5\).

b) Improved energy metabolism: By promoting ketosis, the KD may provide an alternative and more efficient energy source for the CNS, which can be beneficial in MS, where energy metabolism is often impaired\(^5\).

c) Promotion of neuroprotection and remyelination: The KD may enhance the expression of neurotrophic factors and promote oligodendrocyte differentiation, which could contribute to remyelination and neuroprotection in MS\(^5\).

d) Reduction of oxidative stress: The KD has been shown to upregulate antioxidant defenses and reduce the production of reactive oxygen species, which can contribute to the pathogenesis of MS\(^5\).

Ketogenic Diet and Autism Spectrum Disorder (ASD)

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by difficulties in social interaction, communication, and repetitive behaviors. Given the increasing prevalence of ASD and the
limited effectiveness of current treatments, researchers have been exploring alternative therapeutic options, including the ketogenic diet. Several preclinical and clinical studies have indicated that the KD might alleviate some ASD-related symptoms and improve cognitive and social functioning as shown in Table 5.

**Mechanisms Underlying the KD’s Effects in Autism Spectrum Disorder:**

a) Modulation of neurotransmission: The KD has been shown to affect the balance of excitatory and inhibitory neurotransmission, which is often altered in ASD. By modulating the levels of neurotransmitters, the KD may help improve ASD symptoms.

b) Improvement of mitochondrial function: Mitochondrial dysfunction has been implicated in ASD pathogenesis. The KD has been shown to enhance mitochondrial function and biogenesis, which could help alleviate ASD-related symptoms.

c) Reduction of inflammation: The KD has been shown to modulate the immune system and reduce neuroinflammation, which has been implicated in the development of ASD. By reducing inflammation, the KD may help improve the symptoms of ASD.

d) Enhancement of synaptic plasticity: The KD may help improve synaptic plasticity and neuronal connectivity, which are often impaired in individuals with ASD.

**Factors Affecting Ketogenic Diet Success in Neurological Disorders**

1) **Adherence to the diet:** Ensuring strict adherence to the ketogenic diet is crucial for its success in managing neurological disorders. Due to the diet’s restrictive nature, some patients may find it challenging to maintain in the long term, which can limit its therapeutic effects.

2) **Ketosis level:** The degree of ketosis achieved can influence the efficacy of the KD in neurological disorders. Different individuals may require varying levels of ketone bodies for optimal therapeutic effect. Regular monitoring and adjusting the diet to achieve an appropriate level of ketosis is essential for success.

3) **Individual variability:** The response to the KD can vary significantly among individuals. Factors such as genetics, metabolism, and gut microbiota composition may influence an individual’s response to the diet, leading to varying degrees of success.

4) **Type and severity of the neurological disorder:** The efficacy of the KD may be influenced by the specific neurological disorder being treated and its severity. Some conditions may respond better to the KD than others, and further research is needed to determine the optimal application of the diet across various neurological disorders.
5) **Duration of the KD:** The length of time an individual follows the ketogenic diet may impact its effectiveness in managing neurological disorders. Some individuals may require a longer duration on the diet to experience the full range of benefits, while others might see improvements in a shorter period.

6) **Nutritional balance:** Ensuring adequate intake of essential nutrients, such as vitamins, minerals, and protein, is important for the overall success of the KD in managing neurological disorders. Inadequate nutrient intake can potentially lead to adverse effects and may limit the diet’s therapeutic potential.

7) **Age and developmental stage:** The age and developmental stage of an individual may affect their response to the ketogenic diet. For example, younger children with epilepsy may have better seizure control on the diet compared to adolescents or adults. Moreover, adults with neurodegenerative diseases may have different metabolic requirements and comorbidities that could influence the diet’s success.

8) **Comorbid conditions:** The presence of comorbid conditions, such as diabetes, gastrointestinal disorders, or cardiovascular disease, can also affect the success of the ketogenic diet in managing neurological disorders. These conditions may necessitate modifications to the diet or additional medical management to ensure its safety and effectiveness.

**Challenges and Considerations**

Implementing the ketogenic diet (KD) can be challenging for individuals, especially those with neurological disorders, as it requires strict adherence to a high-fat, low-carbohydrate diet. Despite its potential therapeutic benefits, several challenges and considerations should be taken into account when implementing the KD, including potential side effects, nutrient deficiencies, and the need for careful monitoring by healthcare professionals.

**Potential Side Effects:** The KD may cause gastrointestinal disturbances, such as constipation, diarrhea, and vomiting, particularly during the initial adaptation period. These symptoms usually resolve as the body adapts to the new diet. Moreover, long-term adherence to the KD has been associated with an increased risk of cardiovascular disease due to elevated levels of low-density lipoprotein (LDL) cholesterol and saturated fats. However, recent studies suggest that the KD may have neutral or even beneficial effects on cardiovascular health when implemented properly.

**Nutrient Deficiencies:** The restrictive nature of the KD can lead to nutrient deficiencies, especially in vitamins and minerals that are abundant in carbohydrate-rich foods, such as B vitamins, calcium, and potassium. These deficiencies can potentially exacerbate neurological symptoms and impair overall health. To prevent nutrient deficiencies, healthcare professionals may recommend supplementation and regular blood tests to monitor nutrient levels in patients following the KD.

**Monitoring:** Given the potential risks and challenges associated with the KD, careful monitoring by healthcare professionals is essential to ensure the safety and effectiveness of the diet in patients with neurological disorders. Regular consultations with a registered dietitian or nutritionist can help optimize the KD, ensuring adequate nutrient intake and preventing potential complications. Furthermore, healthcare professionals may need to adjust medications or other treatments in response to the patient’s progress on the KD.

By addressing these challenges and closely monitoring patients on the ketogenic diet, healthcare professionals can ensure that the diet is safe, effective, and tailored to the individual's needs. As research into the potential therapeutic effects of the KD for neurological disorders continues to evolve, a better understanding of how to optimize the diet for different patient populations will be critical in maximizing its potential benefits while minimizing risks and complications.

**Conclusion**

In conclusion, the ketogenic diet has demonstrated considerable potential in the management of a range of neurological disorders such as epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and autism spectrum disorder. Although the exact mechanisms underlying these benefits remain to be fully elucidated, the diet presents a promising adjunct therapy for individuals affected by these conditions. As research continues to evolve, efforts should focus on understanding the specific therapeutic mechanisms, optimizing the implementation of the diet, and identifying potential biomarkers that may predict treatment response. By doing so, healthcare professionals can provide personalized and effective treatment strategies for patients with neurological disorders, enhancing their quality of life and overall well-being.

**Acknowledgments**

I would like to express my gratitude to my colleagues and peers for their valuable insights and suggestions during the development of this research article. I also acknowledge the researchers whose work has contributed to the understanding of the ketogenic diet’s role in managing neurological disorders.
Conflict of Interest

The author declares that there is no conflict of interest concerning the research, authorship, or publication of this article. The author has contributed to the conception, design, and preparation of the manuscript and has approved the final version for submission. The author has no financial, personal, or professional relationships with any individuals or organizations that could potentially influence the content of this article in any way.

References
